Downregulation of LncRNA XIST Represses Tumor Growth and Boosts Radiosensitivity of Neuroblastoma Via Modulation of the MiR-375/L1CAM Axis
Overview
Authors
Affiliations
Neuroblastoma (NB) is a heterogeneous tumor that is common in infants and young children. Long non-coding RNA X-inactive specific transcript (XIST) is implicated in NB advancement. Nevertheless, the role and regulatory mechanism by which XIST in NB are not fully elucidated. Expression levels of XIST, microRNA-375-5p (miR-375), and L1 cell adhesion molecular (L1CAM) were examined through quantitative real-time polymerase chain reaction (qRT-PCR). The cell cycle progression, proliferation, and colony formation of NB cells were determined with flow cytometry, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), or cell colony formation assays. Cell apoptotic rate was detected with flow cytometry assay. The relationship between XIST or L1CAM and miR-375 was verified via dual-luciferase reporter assay. The level of L1CAM protein was examined through western blotting. The role of XIST in vivo was confirmed through xenograft assay. XIST and L1CAM were upregulated while miR-375 was downregulated in NB tissues and cells. XIST depletion repressed tumor growth in vivo and elevated radiosensitivity, arrested cell cycle progression, and impeded proliferation of NB cells in vitro. Mechanistically, XIST modulated L1CAM expression through competitively binding to miR-375. Furthermore, miR-375 inhibitor recovered XIST inhibition-mediated effects on the radiosensitivity and malignant behaviors of NB cells. Also, L1CAM overexpression reversed the effects of miR-375 enhancement on the cell cycle progression, proliferation, and radiosensitivity of NB cells. XIST downregulation repressed tumor growth and boosted radiosensitivity of NB via modulating the miR-375/L1CAM axis, indicating that XIST was a promising target for NB treatment.
The Role of Chronic Inflammation in Pediatric Cancer.
Mella C, Tsarouhas P, Brockwell M, Ball H Cancers (Basel). 2025; 17(1.
PMID: 39796780 PMC: 11719864. DOI: 10.3390/cancers17010154.
Exploring the enigma: history, present, and future of long non-coding RNAs in cancer.
Naseer Q, Malik A, Zhang F, Chen S Discov Oncol. 2024; 15(1):214.
PMID: 38847897 PMC: 11161455. DOI: 10.1007/s12672-024-01077-y.
Role of non-coding RNAs in neuroblastoma.
Anoushirvani A, Jafarian Yazdi A, Amirabadi S, Ahmadi Asouri S, Shafabakhsh R, Sheida A Cancer Gene Ther. 2023; 30(9):1190-1208.
PMID: 37217790 DOI: 10.1038/s41417-023-00623-0.
Characterization of m6A-related lncRNA signature in neuroblastoma.
Li L, Chen S, Li J, Rong G, Yang J, Li Y Front Pediatr. 2022; 10:927885.
PMID: 36324814 PMC: 9618704. DOI: 10.3389/fped.2022.927885.
Radio-lncRNAs: Biological Function and Potential Use as Biomarkers for Personalized Oncology.
Kozlowska-Maslon J, Guglas K, Paszkowska A, Kolenda T, Podralska M, Teresiak A J Pers Med. 2022; 12(10).
PMID: 36294743 PMC: 9604926. DOI: 10.3390/jpm12101605.